Shares of Webull Corp (NASDAQ:BULL) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results.

Webull reported second-quarter revenue of $198.83 million, beating estimates of $181.26 million, according to Benzinga Pro. The brokerage platform company posted second-quarter adjusted earnings of five cents per share, beating estimates of 3 cents per share.

Webull shares jumped 13.7% to $9.82 in pre-market trading.

Here are some other stocks moving in pre-market trading.

Gainers

  • Reitar Logtech Holdings Ltd (NASDAQ:RITR) gained 179% to $0.21 in pre-market trading after declining more than 5% on Wednesday.
  • BTC Digital Ltd (NASDAQ:BTCT) rose 105.6% to $1.72 in pre-market trading after jumping 75% on Wednesday.
  • Loop Industries Inc (NASDAQ:LOOP) rose 79% to $1.11 in pre-market trading. The company disclosed in a Form8 filing that it granted ELITe non-transferable, perpetual, exclusive, royalty-bearing license to depolymerization technology and related intellectual property rights o build and operate licensed manufacturing facilities in India.
  • Beam Global (NASDAQ:BEEM) rose 39.6% to $1.69 in pre-market trading after the company reported better-than-expected quarterly financial results.
  • Evaxion A/S (NASDAQ:EVAX) rose 25.5% to $3.95 in pre-market trading. Evaxion, recently, expanded and refocused R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
  • Megan Holdings Ltd (NASDAQ:MGN) rose 54.4% to $0.16 in pre-market trading.
  • BioVie Inc (NASDAQ:BIVI) rose 13.3% to $1.52 in pre-market trading after jumping 39% on Wednesday. BioVie recently posted a fourth-quarter loss of 70 cents per share.
  • Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) gained 11.2% to $29.19 in pre-market trading. Ultragenyx announced the US FDA approval of GENGLYCOS gene therapy, the first-ever FDA-Approved treatment designed to treat the underlying cause of glycogen storage disease Type Ia (GSDIa).
  • Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) shares gained 10% to $4.20 in pre-market trading. Zentalis Pharmaceuticals recently announced the pricing of its $80.5 million proposed public offering of 23 million shares at $3.50 per share.

Losers

  • Tenon Medical Inc (NASDAQ:TNON) tumbled 30.7% to $7.92 in pre-market trading. Tenon Medical shares jumped 109% on Wednesday after the company received a notice of allowance for a U.S. Patent Titled “Systems, Apparatus and Methods for Stabilizing Sacroiliac Joints.”
  • Onfolio Holdings Inc (NASDAQ:ONFO) fell 29.4% to $1.67 in pre-market trading after the company reported second-quarter 2026 results showing lower revenue and a wider loss.
  • OSR Health Inc (NASDAQ:OSRH) declined 28.1% to $0.27 in pre-market trading. OSR Health said it plans to request panel hearing after receiving Nasdaq delisting determination.
  • Surgepays Inc (NASDAQ:SURG) fell 23.6% to $0.19 in pre-market trading. SurgePays, on Friday, reported better-than-expected second-quarter financial results.
  • Matinas BioPharma Holdings Inc (NYSE:MTNB) fell 22.1% to $0.19 in pre-market trading after gaining 18% on Wednesday.
  • Autozi Internet Technology (Global) Ltd (NASDAQ:AZI) fell 19.3% to $1.34 in pre-market trading. Autozi Internet Technology shares jumped 44% on Wednesday after the company announced that it has received an aggregate investment of $30 million from multiple investors.
  • Yunji Inc (NASDAQ:YJ) fell 20.2% to $3.39 in pre-market trading after jumping 144% on Wednesday.
  • Moderna Inc (NASDAQ:MRNA) fell 12.4% to $153.01 in pre-market trading. Moderna shares jumped 177% on Wednesday after the company and Merck announced topline results from the Phase 3 INTerpath-001 trial met its primary and a key secondary endpoint.
  • Wolfspeed Inc (NYSE:WOLF) fell 12% to $25.60 in pre-market trading after the company reported mixed fourth-quarter financial results.
  • Coty Inc (NYSE:COTY) fell 7.7% to $2.80 in pre-market trading after the company reported mixed fourth-quarter financial results and issued first-quarter adjusted EPS guidance below estimates. The company disclosed that the Gucci Beauty license exit will result in a step-down in FY28 sales and profit.

Photo via Shutterstock